Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update Cash position of 9.7 million as of June 30, 2026 Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 BioChaperone feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies Regulatory News: Adocia (Euronext Paris: FR0011184241 ADOC, the Company), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update
Peixoto, R
But Stephen doesn't need you to buy into some sort of belief or new framework
The well-balanced formulation ensures optimal replenishment of essential nutrients, promoting neurological health and energy production
Not intended for human or animal consumption, medical use, or therapeutic use
US$ 24.96
US$ 21.30
US$ 27.41
US$ 26.37
US$ 29.23
US$ 21.57
US$ 28.73
US$ 27.87